Nateglinide - current and future role in the treatment of patients with type 2 diabetes mellitus

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)

Abstract

Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial glucose levels. Nateglinide, a d-phenylalanine derivative, restores postprandial early phase insulin secretion in a transient and glucose-sensitive manner without affecting basal insulin levels. As nateglinide is administered immediately before meals it provides greater lifestyle flexibility than agents that require patients to eat to avoid hypoglycemic events (e.g. long-acting sulfonylureas). In randomised, double-blind trials in patients with type 2 diabetes, nateglinide monotherapy (mealtime treatment of 120 mg three times daily) significantly improved long-term glycaemic control by significantly reducing glyated haemoglobin (HbA(1c)) and preventing mealtime glucose spikes. The combination of nateglinide with insulin-sensitising agents, for example, metformin and thiazolidinediones, addresses the dual defects of loss of insulin secretion and insulin resistance to provide optimal management of type 2 diabetes, and more patients achieve HbA(1c) goal with nateglinide combination therapy rather than with monotherapy with other oral agents. Nateglinide also restores early insulin secretion and reduces postprandial hyperglycaemia in prediabetic subjects with impaired glucose tolerance (IGT) and appears similarly effective in elderly and non-elderly populations with type 2 diabetes. It has an excellent safety and tolerability profile, with a low propensity to cause hypoglycaemia due to its transient, selective effect on early phase insulin secretion. Nateglinide as monotherapy or combination therapy is an effective option to reduce mealtime glucose in patients with type 2 diabetes. The results of ongoing research into its potential role in delaying progression to overt diabetes, and protecting against cardiovascular events, in prediabetic patients with IGT are awaited.

Original languageEnglish
Pages (from-to)1218-1228
Number of pages11
JournalInternational Journal of Clinical Practice
Volume59
DOIs
Publication statusPublished - Oct 2005

Keywords

  • postprandial hyperglycaemia
  • early phase insulin secretion
  • nateglinide
  • D-phenylalanine derivative
  • rapid-acting secretagogue
  • EARLY INSULIN-SECRETION
  • HYPOGLYCEMIC AGENT NATEGLINIDE
  • OXIDATIVE STRESS GENERATION
  • POSTPRANDIAL HYPERGLYCEMIA
  • GLYCEMIC CONTROL
  • GLUCOSE-METABOLISM
  • ENDOTHELIAL DYSFUNCTION
  • FASTING HYPERGLYCEMIA
  • SIMVASTATIN TREATMENT
  • COMBINATION THERAPY

Fingerprint

Dive into the research topics of 'Nateglinide - current and future role in the treatment of patients with type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this